Effect of the HMGB1、CEA and SCC-Ag by paclitaxel combined with cisplatin chemotherapy in advanced esophageal cancer
10.3969/j.issn.1005-1678.2017.02.050
- VernacularTitle:紫杉醇联合顺铂化疗方案对进展期食管癌患者HMGB1、CEA、SCC-Ag水平的影响
- Author:
Wei HU
;
Shubo DING
;
Hongyong WANG
;
Huijuan HE
;
Xiaofang LIAO
;
Wansu XU
- Keywords:
paclitaxel;
cisplatin;
combine;
advanced esophageal cancer;
HMGB1;
CEA;
SCC-Ag
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(2):165-167
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of the high mobility group protein 1 (HMGB1), cancer embryonic antigen (CEA) and squamous cell carcinoma antigen ( SCC-Ag) by paclitaxel combined with cisplatin chemotherapy in the treatment of advanced esophageal cancer patients .Methods 43 cases advanced esophageal cancer patients from our hospital were selected and randomly divided into the control group and the experiment group.19 cases in the control group were treated by surgery combined with postoperative chemotherapy , 24 cases in the experimental group were treated with surgery and chemotherapy.The clinical efficacy and high mobility group protein 1 ( HMGB1 ) , cancer embryonic antigen ( CEA ) and squamous cell carcinoma antigen ( SCC-Ag ) levels were compared between the two groups before and after treatment.Results The total effective rate of the experimental group was (91.7%) higher than that of the control group (57.9%), the difference was statistically significant (P <0.05).After treatment, the serum levels of SCC-Ag, CEA and HMGB1 were decreased in the two groups, compared with the control group, the experimental group SCC-Ag, CEA and HMGB1 levels were lower, the difference was statistically significant ( P <0.05 ) .There was no significant difference in adverse reactions between the two groups.Conclusion Paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer patients with good results, presumably with the decrease of serum SCC-Ag, CEA and HMGB1 levels in patients with.
